Array Biopharma (ARRY) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts ARRY Hot Sheet
Price: $3.96 -2.7%
EPS Growth %: -70.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -70.0%
Financial Fact:
Interest income: 70K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Array Biopharma (NASDAQ: ARRY) reported Q2 EPS of ($0.14), $0.04 better than the analyst estimate of ($0.18). Revenue for the quarter came in at $44.52 million versus the consensus estimate of $30.99 million.
COLUMBUS / BRAF-mutant melanoma New Drug Application (NDA) expected to file in June or July
NEMO / NRAS-mutant melanoma target action date under the Prescription Drug User Fee Act (PDUFA) on June 30, 2017
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- KB Home (KBH) Tops Q3 EPS by 16c
- H.C. Wainwright Reiterates Buy Rating on AnaptysBio (ANAB)
- Ennis (EBF) Misses Q2 EPS by 2c
Create E-mail Alert Related Categories
Earnings, FDA, GuidanceRelated Entities
Earnings, PDUFASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
